BeOne Medicines Deepens InSysBio Partnership To Refine Oncology Trial Risk [Yahoo! Finance]
AstraZeneca PLC Ordinary Shares (AZN)
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
BeOne Medicines, ticker NasdaqGS:ONC, extended its collaboration with InSysBio to apply mechanistic translational modeling to clinical trial design. The expanded partnership focuses on refining dosing regimens and addressing safety concerns such as cytokine release syndrome. The companies aim to use advanced modeling tools to inform future trial planning and support BeOne Medicines' drug development programs. For you as an investor, this move connects directly to how BeOne Medicines runs its trials and manages risk across its pipeline. The company operates in an industry where immunology and complex biological pathways are central, and modeling approaches like this are becoming more common as drug developers look for data driven ways to design studies. By incorporating more modeling into trial planning, BeOne Medicines is looking to clarify dose selection and safety questions earlier in development, which can be important for patient protection and for keeping studies on trac
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC Ordinary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- AstraZeneca (NASDAQ:AZN) had its "sell" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- Shell chief exec to become one of FTSE's best paid bosses [Yahoo! Finance]Yahoo! Finance
- Why pharma manufacturers are still investing in Europe [Yahoo! Finance]Yahoo! Finance
- IonQ to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]Yahoo! Finance
- AstraZeneca Oncology Advances Gain Momentum With New Cancer Approvals In Focus [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 2/3/26 - Form S-8
- 2/3/26 - Form 6-K
- 2/2/26 - Form 6-K
- AZN's page on the SEC website